EDEN PRAIRIE, Minn., April 05, 2018 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ:CHFS) announced today the initiation of a new distribution agreement with Dimedix Surgical to distribute the company’s Aquadex FlexFlow System in Spain.
"Annual hospitalizations for heart failure exceed 1 million in Europe, and more than 90% are due to fluid overload,” commented John Erb, chairman and chief executive officer of CHF Solutions. “Our distribution agreement with Dimedix Surgical expands our existing reach in Europe and provides physicians in Spain the opportunity to treat these patients with the Aquadex FlexFlow system when diuretics are no longer effective.”
Terms of the agreement were not disclosed.
About CHF Solutions
CHF Solutions, Inc. (NASDAQ:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for Aquapheresis® therapy. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company's mission is to predict, measure, and control patient fluid balance through science, collaboration, and innovative medical technology. CHF Solutions is a Delaware corporation headquartered in Minneapolis, Minnesota with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the NASDAQ Capital Market since February 2012.
Claudia Napal Drayton
Chief Financial Officer
CHF Solutions, Inc.
JQA Partners, Inc.
Source: CHF Solutions, Inc.